Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver

Makoto Fujimoto, Koichi Tsuneyama, Mosaburo Kainuma, Nobuyasu Sekiya, Hirozo Goto, Yasuo Takano, Katsutoshi Terasawa, Carlo Selmi, M. Eric Gershwin, Yutaka Shimada

研究成果: ジャーナルへの寄稿記事

23 引用 (Scopus)

抜粋

Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1% cholesterol, or each of the five experimental treatments (Kampo formulas 1% keishibukuryogan [KBG], 1% orengedokuto [OGT], and 1% shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1% cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2′-deoxyguanosine (P < 0.05), hepatic α-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.

元の言語英語
ページ(範囲)328-337
ページ数10
ジャーナルExperimental Biology and Medicine
233
発行部数3
DOI
出版物ステータス出版済み - 3 1 2008

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

これを引用

Fujimoto, M., Tsuneyama, K., Kainuma, M., Sekiya, N., Goto, H., Takano, Y., ... Shimada, Y. (2008). Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver. Experimental Biology and Medicine, 233(3), 328-337. https://doi.org/10.3181/0707-RM-207